Clinical Trial

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2020 (before its estimated December 2022 completion). Its status may not reflect the trial's current state.
Summary
Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
Trial Details
NCT Number NCT04286841
Lead Sponsor Guangdong Association of Clinical Trials
Conditions Immunotherapy, Lung Cancer
Enrollment 100 participants
Start Date 2019-05-01
Primary Completion 2022-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2020-02-27